BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL)

FairStock Score: 42/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach any security by asking whether the underlying business has durable earning power and a margin of safety. Here, the answer is no. BriaCell is an immuno-oncology developer with a Phase 3 asset, Bria-IMT, plus earlier programs, but the filed figures show no revenue in fiscal Q3 2026 (quarter ended 2026-04-30), fiscal Q2 2026, fiscal Q1 2026, FY2025, FY2024, or FY2023. In fiscal Q3 2026, net income was -$7.2M and diluted EPS -$0.99; fiscal Q2 2026 lost -$7.2M, or -$2.58 per diluted share; fiscal Q1 2026 lost -$8.2M, or -$4.35 per diluted share. FY2025 lost -$26.3M, or -$62.19 per diluted share, and FY2024 lost -$4.8M, or -$43.68. This is not a business that compounds owner earnings; it consumes capital. FairStock's calculations show ROE of -175.25% and ROCE of -90.84%, with a P/B of 0.29 based on the 2026-09-04 close of $0.95. A low P/B might tempt a Graham-style investor, but book value in a loss-making biotech is mostly cash being burned, not productive assets. The Lynch category is none because the company lost money in each of the last four years, and the FairStock Score is 42/100. For the warrant expiring 2031, I cannot compute intrinsic value without the strike and terms; it is a leveraged, time-limited claim on a speculative equity. The upside depends on clinical success, not on present earnings. I prefer to watch from the sidelines until the business can generate revenue or at least demonstrate a credible path to profitability without endless dilution.

In plain English: BriaCell is a cancer drug developer with a lead treatment in Phase 3 testing, but its filed reports show no revenue and continuing losses. The business looks weak on the numbers: it has lost money for years and has deeply negative returns. At 95 cents, with no sales or profits to judge, the price looks speculative rather than clearly cheap, even though it trades below its reported book value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-09-04 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-04-30) · fiscal Q2 2026 10-Q (period ended 2026-01-31) · fiscal Q1 2026 10-Q (period ended 2025-10-31) · fiscal Q3 2025 10-Q (period ended 2025-04-30) · FY2025 10-K (period ended 2025-07-31) · FY2024 10-K (period ended 2024-07-31) · FY2023 10-K (period ended 2023-07-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer